Having been studied extensively over the past few decades, A549 cells have become one of the major players in the lung carcinoma field. With numerous applications in cell signaling studies and cancer oncogene evaluations, A549 xenografts have become prime targets for transfection experiments and related research. The cells are set apart by their ability to synthesize lecithin and their internal environment; a high level of unsaturated fatty acids that contribute to the maintenance of membrane phospholipids in lung epithelial cells. The cell line has been used extensively as an in vitro host capable of receiving nucleic acids and responding effectively in drug metabolism studies.
A549 is an adenocarcinomic cell line that was established in 1972 from the lung tissue of a 58-year-old Caucasian male. A549 is categorized as a non-small-cell lung carcinoma, which is more common yet less aggressive than small cell lung carcinoma. A549 cells are hypotriploid, have a modal chromosome number of 66, and exhibit an epithelial-like morphology with adherent cultural properties. A549 cells are suitable transfection hosts for in vivo and in vitro models, and an A549 Transfection Reagent can be found at Altogen Biosystems . An A549 xenograft model drawn from an in vivo transfection can be found here . The A549 cell line widely serves as a model for the study of not only lung adenocarcinoma, but also respiratory infections, asbestos exposure, and viral infections stemming from asthma.
Comments
Post a Comment